Patents Assigned to New York University Medical Center
-
Patent number: 7736623Abstract: A method is disclosed for providing a correcting factor for the dilution of measurements of at least one biomarker in cerebrospinal fluid (CSF). The method comprises providing semi-automated measurements of the ventricular system by MRI scans using quantitative anatomical protocols, determining a measurement of biomarker levels in CSF that has been extracted, correcting the measurement of the level of said at least one biomarker according to the ventricular size, and providing a corrected result of the measurement determined in step (b), said corrected result accounting for concentration dilution due to the change in ventricular size. The method is particularly suited for the measurement of all biomarkers found in the CSF, such as those associated with mild cognitive impairment (MCI) and Alzheimer's Disease.Type: GrantFiled: March 20, 2003Date of Patent: June 15, 2010Assignee: New York University Medical CenterInventors: Mony De Leon, Henry Rusinek
-
Patent number: 7348178Abstract: The present invention relates to a novel Ad based packaging system that can be used for incorporation of heterologous DNA into infectious but replication defective viral particles. The components of the invention include an “artificial genome”, i.e., a recombinant vector which contains elements that function as adenovirus replication and packaging signals flanking an intervening DNA sequence. The elements may comprise the minimum genomic Ad sequences required to direct replication of heterologous DNA and packaging into viral particles. The system also includes a means for expressing complementing helper functions to provide in trans viral proteins required for replication and packaging of recombinant viral vectors, but without contaminating the stock of recombinant, trans-packaged viral particles.Type: GrantFiled: October 17, 1996Date of Patent: March 25, 2008Assignee: New York University Medical CenterInventor: Robert J. Schneider
-
Publication number: 20070009524Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: ApplicationFiled: January 10, 2002Publication date: January 11, 2007Applicants: New York University Medical Center, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 6790444Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: January 8, 2001Date of Patent: September 14, 2004Assignees: New York University Medical Center, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Publication number: 20030175837Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.Type: ApplicationFiled: July 2, 2001Publication date: September 18, 2003Applicant: New York University Medical CenterInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 6576442Abstract: The present invention features a method for treatment of an organism having a disease or condition characterized by an abnormality in a signal transduction pathway, wherein the signal transduction pathway includes a rdgB protein. The invention also features methods for diagnosing such diseases and for screening for agents that will be useful in treating such diseases. The invention also features purified and/or isolated nucleic acid encoding a rdgB protein.Type: GrantFiled: June 7, 2000Date of Patent: June 10, 2003Assignees: Sugen, Inc., New York University Medical CenterInventors: Sima Lev, Gregory D. Plowman, Joseph Schlessinger
-
Patent number: 6565845Abstract: The present invention relates to a method for implanting producer cells into the mammalian brain. The producer cells are engineered with a retroviral based recombinant vector encoding a tumorcidal factor or susceptibility factor that confers on tumor cells sensitivity to chemotherapeutic or radiotherapeutic agents. Prior to transplantation into the mammalian brain, the producer cells are first cultured in vitro on a support matrix to increase the long-term viability of the transplanted cells and to provide long-term functional benefit.Type: GrantFiled: December 4, 2000Date of Patent: May 20, 2003Assignees: Titan Pharmaceuticals, Inc., New York University Medical CenterInventors: Bruce Cherksey, Louis R. Bucalo
-
Publication number: 20030054004Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr;(TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: ApplicationFiled: January 10, 2002Publication date: March 20, 2003Applicant: New York University Medical CenterInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Publication number: 20030032596Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.Type: ApplicationFiled: July 15, 2002Publication date: February 13, 2003Applicant: New York University Medical CenterInventors: Robert J. Schneider, Nicola Klein
-
Publication number: 20020146419Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: ApplicationFiled: January 10, 2002Publication date: October 10, 2002Applicant: New York University Medical CenterInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Publication number: 20020141996Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: ApplicationFiled: January 10, 2002Publication date: October 3, 2002Applicant: New York University Medical Center and Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Publication number: 20020114805Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: ApplicationFiled: December 7, 2001Publication date: August 22, 2002Applicant: New York University Medical CenterInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 6420338Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.Type: GrantFiled: June 13, 1997Date of Patent: July 16, 2002Assignee: New York University Medical CenterInventors: Robert J. Schneider, Nicola Klein
-
Patent number: 6391584Abstract: The present invention relates to a novel method, based on direct expression cloning, for identifying target proteins capable of binding to and/or serving as substrates for receptor or cytoplasmic tyrosine kinases. The present invention also relates to novel proteins identified using this method, and to methods for identifying compounds that disrupt the interaction of such novel proteins with the receptor or cytoplasmic tyrosine kinases.Type: GrantFiled: March 29, 1999Date of Patent: May 21, 2002Assignee: New York University Medical CenterInventors: Joseph Schlessinger, Edward Y. Skolnik, Benjamin L. Margolis
-
Publication number: 20020022720Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: ApplicationFiled: August 10, 2001Publication date: February 21, 2002Applicant: New York University Medical CenterInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 6310181Abstract: The present invention relates generally to a newly identified adaptor protein FRS2 and related products and methods. FRS2 links protein kinases to activating partners in cells. The invention also relates to nucleic acid molecules encoding portions of FRS2, nucleic acid vectors containing FRS2 related nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that enhance or block FRS2 interactions with natural binding partners. Also disclosed are methods for diagnosing abnormal conditions in an organism with FRS2 related molecules or compounds.Type: GrantFiled: December 1, 1997Date of Patent: October 30, 2001Assignee: New York University Medical CenterInventors: Haruhiko Kouhara, Taly Spivak-Kroizman, Irit Lax, Joseph Schlessinger
-
Patent number: 6284471Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.Type: GrantFiled: February 4, 1994Date of Patent: September 4, 2001Assignees: New York University Medical Center, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Dadonna, John Ghrayeb, David Knight, Scott A. Siegel
-
Patent number: 6277969Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: August 12, 1998Date of Patent: August 21, 2001Assignees: New York University, Centocor, Inc., New York University Medical CenterInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 6210664Abstract: The present invention relates to a method for implanting producer cells into the mammalian brain. The producer cells are engineered with a retroviral based recombinant vector encoding a tumorcidal factor or susceptibility factor that confers on tumor cells sensitivity to chemotherapeutic or radiotherapeutic agents. Prior to transplantation into the mammalian brain, the producer cells are first cultured in vitro on a support matrix to increase the long-term viability of the transplanted cells and to provide long-term functional benefit.Type: GrantFiled: April 8, 1996Date of Patent: April 3, 2001Assignees: New York University Medical Center, Titan Pharmaceuticals, Inc.Inventors: Bruce Cherksey, Louis R. Bucalo
-
Patent number: 6045797Abstract: A method for treatment of a disease or condition in an organism characterized by an abnormal level of interaction between a BLM domain and its natural binding partner is described. The disease or condition may also be characterized by an abnormality in a signal transduction pathway, wherein the pathway contains a protein with a BLM domain. The method includes disrupting or promoting that interaction (or signal) in vivo. The method also involves inhibiting the activity of the complex formed between the BLM domain-containing protein and its natural binding partner. A method for diagnosis of such a disease or condition by detecting the level of such interaction as an indication of that disease or condition is also described. Also, a method for screening for an agent useful for treatment of such a disease or condition by assaying potential agents for the ability to disrupt or promote that interaction is described.Type: GrantFiled: May 30, 1997Date of Patent: April 4, 2000Assignee: New York University Medical CenterInventors: Ben Lewis Margolis, Joseph Schlessinger